<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053035</url>
  </required_header>
  <id_info>
    <org_study_id>AL001-ALS-201</org_study_id>
    <nct_id>NCT05053035</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in C9orf72-Associated Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alector Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alector Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase 2 double-blind, placebo-controlled study of AL001 in participants with&#xD;
      C9orf72-associated ALS.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 2 double-blind, placebo-controlled trial to test the safety, tolerability,&#xD;
      pharmacokinetics, and pharmacodynamics of AL001 in participants with C9orf72-associated&#xD;
      Amyotrophic Lateral Sclerosis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2, 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability of AL001 measured by number of subjects with adverse events</measure>
    <time_frame>32 weeks</time_frame>
    <description>Incidence of adverse events during the study treatment period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) of AL001</measure>
    <time_frame>32 weeks</time_frame>
    <description>Concentration of AL001 at specified time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) for AL001</measure>
    <time_frame>32 weeks</time_frame>
    <description>Evaluate Cmax for concentration of AL001 at specified time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve concentration (AUC) for AL001</measure>
    <time_frame>32 weeks</time_frame>
    <description>Evaluate AUC for concentration of AL001 at specified time points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in serum progranulin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Evaluate serum progranulin levels at pre-specified timepoints</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in CSF progranulin</measure>
    <time_frame>32 weeks</time_frame>
    <description>Evaluate CSF progranulin levels at pre-specified timepoints</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in plasma neurofilament light chain</measure>
    <time_frame>32 weeks</time_frame>
    <description>Evaluate plasma neurofilament light chain levels at pre-specified timepoints</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CSF neurofilament light chain</measure>
    <time_frame>32 weeks</time_frame>
    <description>Evaluate CSF neurofilament light chain levels at pre-specified timepoints</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>AL001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AL001 every 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo every 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AL001</intervention_name>
    <description>Administered via intravenous (IV) infusion</description>
    <arm_group_label>AL001</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered via intravenous (IV) infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmation of C9orf72 mutation&#xD;
&#xD;
          -  Diagnosis of ALS by revised El Escorial criteria&#xD;
&#xD;
          -  Time since onset of muscle weakness due to ALS ≤36 months at the time of the Screening&#xD;
             Visit&#xD;
&#xD;
          -  Slow Vital Capacity (VC) ≥50% of predicted capacity at the time of the Screening Visit&#xD;
&#xD;
          -  If taking riluzole, must be on a stable dose of riluzole for at least 30 days prior to&#xD;
             the Screening Visit. Riluzole naive participants are allowed.&#xD;
&#xD;
          -  If taking edaravone, must have completed at least one cycle of edaravone prior to the&#xD;
             Screening Visit and plan to continue edaravone during the study. Edaravone naive&#xD;
             participants are allowed.&#xD;
&#xD;
          -  Females must not be pregnant, breastfeeding or planning to conceive within the study&#xD;
             period. Males must agree to use acceptable contraception&#xD;
&#xD;
          -  Capable of providing informed consent at the Screening visit and complying with study&#xD;
             procedures throughout the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically significant, unstable, medical condition (other than ALS)&#xD;
&#xD;
          -  Clinically significant heart disease, liver disease or kidney disease&#xD;
&#xD;
          -  Cognitive impairment or dementia&#xD;
&#xD;
          -  Current uncontrolled hypertension&#xD;
&#xD;
          -  History of unresolved cancer&#xD;
&#xD;
          -  Any experimental gene therapy&#xD;
&#xD;
          -  Any experimental vaccine (any vaccine against COVID-19 either approved or administered&#xD;
             under an Emergency Use Authorization is allowed)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katharine Nicholson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Study Lead</last_name>
    <email>clinicaltrials@alector.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Barrow Neurological Instiute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

